Seven of ten patients remained alive 19–37 months after a single intratumoral injection of ultra‑high concentration nitric oxide (UNO) in a Phase 1 proof‑of‑concept trial, with two triple‑negative breast cancer patients reported as having no evidence of disease at last follow‑up. Safety was favorable, with most treatment‑related adverse events Grade 1. One treatment‑related serious adverse event, hypoxia during administration at 25,000 ppm, resolved and was not dose‑limiting. No deaths occurred within 12 weeks post‑treatment. Dosing cohorts included 25,000 ppm (n=6) and 50,000 ppm (n=4).
The data, to be presented in a poster at AACR 2026, come from NCT05351502, which enrolled ten heavily pretreated patients with unresectable cutaneous or subcutaneous primary or metastatic lesions across breast cancer (n=6), squamous cell carcinoma (n=2), and melanoma (n=2). Participants had received a mean of 5.5 prior systemic therapies and 10.3 total cancer‑directed treatments. The intervention was a single intratumoral administration of UNO as monotherapy; the company indicates the AACR poster will include analyses beyond the abstract now visible in the meeting planner.
Strategically, Beyond Cancer is testing whether localized, non‑viral ablation with ultra‑high concentration nitric oxide can trigger clinically meaningful control and potential immune priming without the manufacturing and biosafety baggage of oncolytic viruses or the mixed results seen with intratumoral STING agonists and cytokine payloads. The bet is that a one‑time, brief procedure can create a systemic effect that later pairs cleanly with PD‑1 inhibitors. That positioning differentiates the program in a crowded intratumoral field, but it also shifts the risk profile toward procedural logistics and device‑drug integration: delivering 25,000–50,000 ppm NO directly into tumor tissue requires specialized equipment, gas handling controls, and respiratory monitoring—an operational footprint distinct from standard office‑based injections.
For sites, this approach favors centers comfortable with dermatologic oncology, surgical oncology, or interventional techniques for superficial lesions. Stand‑up will likely involve device installation, staff training on high‑concentration NO delivery, room safety protocols, and peri‑procedural monitoring to mitigate hypoxia risk. CROs should anticipate small, procedure‑intensive studies with real‑time safety oversight and imaging‑anchored assessments that capture both injected‑lesion outcomes and potential effects on distant disease. For sponsors and regulators, the key evidentiary question is systemic impact: reductions in non‑injected lesions, immune activation signals, and durable control that justify moving from monotherapy proof‑of‑concept to checkpoint combinations or earlier lines. Payers and health systems will look for operational simplicity and reproducibility relative to device‑heavy or viral platforms, balanced against the facility modifications and training this gas‑based modality may require.
The signal is provocative but early. The dataset is small, heterogeneous, and uncontrolled; survival observations in end‑stage patients warrant cautious interpretation absent standardized response rates, durability metrics, and biomarker corroboration. What to watch at AACR: objective responses by RECIST/iRECIST in injected and non‑injected lesions, dose‑response between 25,000 and 50,000 ppm, evidence of immune activation in tumor microenvironment and peripheral blood, and clarity on the safety envelope during and immediately after administration. Equally important is Beyond Cancer’s next study architecture—whether it moves to expansion cohorts in select histologies, introduces PD‑1 combinations with randomized arms, and defines operational requirements for broader site participation. The regulatory path will likely run through combination‑product oversight, with device validation, human‑factors work, and facility readiness becoming gating items alongside clinical efficacy. The open questions are generalizability beyond cutaneous or subcutaneous disease, scalability across community sites, and whether the platform can produce consistent systemic effects that translate into registrational endpoints.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
